TREATMENT DECISION MAKING FOR EARLY PROSTATE CANCER

描述：（申请人的描述）学术生涯奖将 帮助申请人实现短期和长期的职业生涯 目标. 他的近期职业目标是开发一个研究项目， 检查早期前列腺患者的治疗决策 癌症，并评估干预，将减少痛苦， 有助于做出治疗决策。 从长远来看，学术生涯 奖学金将帮助申请人获得心理社会方面的专门培训 成为癌症预防领域的独立研究者。 福克斯大通癌症中心（FCCC）提供了一个环境丰富的两个方面 学术和临床资源。 一个宝贵的资源，申请人的 教育将有机会与博士苏珊娜M。米勒， 在行为医学和癌症方面有着良好背景的研究者 预防研究。 高级官员将提供进一步的支持。 放射肿瘤学、泌尿学和外科领域的研究人员，以及 生物统计学 FCCC为申请人提供了一个广泛而多样的 人口基数。 提出了两项研究。 研究1是一项心理调查， 决定男性治疗决策的社会因素 被诊断为早期前列腺癌 建议的调查， 迄今为止规模最大的一次，涉及寻求第二次治疗的患者。 关于手术和放射治疗的意见，以及 前列腺活检后被诊断为前列腺癌。 患者 在决策阶段、治疗阶段和四个阶段接受采访。 在接下来的18个月里， 决定和性/泌尿功能。 研究2将纳入 研究1中的信息在设计和评价干预措施时， 寻址认知（例如，对疾病的误解）和情绪 因素（例如，癌症），这可能会干扰决策。 的 建议的干预措施的有效性和可行性将在一个 随机对照试验。

DESCRIPTION: (Applicant's Description) The Academic Career Award will assist in the achievement of the applicant's immediate and long-term career goals. His immediate career goal is to develop a program of research that examines treatment decision making among men with early stage prostate cancer and that evaluates an intervention that will reduce distress and facilitates treatment decision making. In the long-term the Academic Career Award will assist the applicant to obtain specific training in psycho-social oncology to become an independent researcher in cancer prevention. Fox Chase Cancer Center (FCCC) offers an environment rich in terms of both academic and clinical resources. An invaluable resource to the applicant's education will be the opportunity to work with Dr. Suzanne M. Miller, an investigator with excellent background in behavioral medicine and cancer prevention research. Further support will be available from senior investigators in the fields of radiation oncology, urology, and surgery, and biostatistics. FCCC offers the applicant access to a large and varied population base. Two studies are proposed. Study 1 is an investigation of the psychological and social factors that determine treatment decision-making among men diagnosed with early stage prostate cancer. The proposed survey, the largest of its kind to date, involves patients who are seeking second opinions about surgery and radiation treatment, as well as patients who were diagnosed with prostate cancer after they had a prostate biopsy. Patients are interviewed during the decision making phase, treatment phase and four more times during the following 18 months, to assess satisfaction with the decision and sexual/urinary functioning. Study 2 will incorporate information from Study 1 in the design and evaluation of an intervention by addressing cognitive (e.g., misconception about the disease) and emotional factors (e.g., cancer worry) that might interfere with decision making. The efficacy and feasibility of the proposed intervention will be assessed in a randomized controlled trial.